Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gulati, S.
Right arrow Articles by Gupta, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gulati, S.
Right arrow Articles by Gupta, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 2013-2017
© 2001 European Renal Association-European Dialysis and Transplant Association

Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome

Sanjeev Gulati1,, Saurabh Pokhariyal1, Raj Kumar Sharma1, Ravi Elhence1, Vijay Kher1, Chander Mohan Pandey2 and Amit Gupta1

1 Department of Nephrology and 2 Department of Biostatistics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow, India

Background. The treatment of frequently relapsing (FR) and steroid-dependent (SD) idiopathic nephrotic syndrome (INS) with oral cyclophosphamide (OCP) poses problems of compliance, side-effects and infections.

Methods. We prospectively evaluated the usefulness of intravenous cyclophosphamide (IVCP) in children with steroid sensitive INS who were frequent relapsers or steroid dependent. Fifty-one children were included in the study of whom 22 were FR and 29 were SD. IVCP was administered in a dose of 500 mg/m2/month for 6 months after achieving a steroid-induced remission. The response to IVCP was evaluated in terms of remission, change in the steroid response status of the patient, duration of remission (i.e. proteinuria-free days), side effects and compliance with therapy.

Results. The proteinuria-free days (mean 19.9±3.5 before IVCP therapy vs 1256±167 days after IVCP therapy) (P<0.00001), and serum albumin levels (23±1.6 g/l before IVCP therapy vs 34±2 g/l after IVCP therapy) (P<0.001) were significantly higher following IVCP therapy. The cumulative remission rate in the study group was 49% at 5 years and was comparable to that achieved with oral cyclophosphamide at a 40% lower cumulative dose.

Conclusions. We conclude that IVCP is a safe and effective therapeutic modality in children with INS who are FR and SD. Its efficacy is comparable to the results obtained with oral cyclophosphamide based on historical comparisons with previous studies.

Keywords: cyclophosphamide; frequent relapses; nephrotic syndrome

Correspondence and offprint requests to: Dr Sanjeev Gulati, Assistant Professor, Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, India. Email: sgulati{at}sgpgi.ac.in


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
A. F. Donia, S. H. Gazareen, H. A. Ahmed, F. E. Moustafa, A. A. Shoeib, A. M. Ismail, S. Khamis, and M. A. Sobh
Pulse cyclophosphamide inadequately suppresses reoccurrence of minimal change nephrotic syndrome in corticoid-dependent children
Nephrol. Dial. Transplant., October 1, 2003; 18(10): 2054 - 2058.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.